$BIO

Harvard Bioscience, Inc. reported strong Q4 2025 earnings, exceeding Wall Street estimates. The company highlighted robust demand in its biotechnology segment, driven by increasing investments in research and development. Management provided an optimistic outlook for 2026, forecasting significant revenue growth. However, they acknowledged potential risks related to supply chain disruptions and inflationary pressures. Overall, the earnings call has generated positive sentiment among investors looking for growth in the biotech sector.